Want to see AU:MVP full AI Analyst Report?
Earnings Data
Report Date
Aug 20, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
>-0.01Last Year’s EPS
>-0.01Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of positive operational progress and near-term headwinds. Highlights include 8% group revenue growth, strong Pain Management momentum (+18%), positive operating cash flow, published pediatric data and imminent Europe pediatric approvals, pricing actions expected to add ~A$1m margin, and early partner traction (France +10%). Offsetting these are meaningful Respiratory weakness driven by a 16% U.S. decline and overall segment -10%, a ~$1.1m FX drag, short-term earnings impact from partner transitions (~$600k) and higher medical/commercial spending (~$500k), plus U.S. tariff uncertainty and market valuation concerns. On balance the company shows clear strategic progress and improved underlying performance when adjusted for FX, but near-term respiratory softness and transition-related impacts temper the outlook.Company Guidance
Group Revenue Growth
Group revenue increased 8% in FY '26 H1 versus prior period, reflecting stronger underlying performance.
Pain Management Outperformance
Pain Management revenue rose 18% driven by higher Penthrox volumes and improved pricing in Australia.
Regional Volume Gains
Penthrox volumes grew across all regions: Europe underlying demand +10% (U.K. & Ireland +8%, France +10%, Nordic +16%), Australia volume +9% (hospital segment +26%), and Rest of World markets showing strong growth.
Positive Operating Cash Flow and Strong Balance Sheet
Operating cash flow was positive at $300,000, an improvement of $1.0m versus prior year; cash at period end was $16.9m, and free cash flow improved with slightly lower CapEx.
Pediatric Label Progress and MAGPIE Publication
MAGPIE pediatric study published; nearing final approvals for pediatric indication (age 6+) in Europe with device approval received and expectation of country-level approvals by August, broadening addressable market and enabling ambulance trust adoption.
Evidence Generation and Health Economics Work
Completed a health economic study showing ED cost and operational savings for Penthrox (publication expected by end FY '26) and supporting multiple real-world evidence studies to aid adoption.
Commercial and Regulatory Momentum
Increased on‑the‑ground commercial and medical efforts, extension of PBS prescriber eligibility to nurse practitioners in Australia, and partners (Ethypharm, Labatec) mobilized to expand market access.
Pricing Actions Supporting Margins
July pricing increases in Australia moved remaining ~25% of Australian volume to new prices (aligned with PBS), expected to deliver ~A$1m margin improvement in FY '26.
Early Partner Success in France
After Ethypharm field deployment, France volumes were reported up ~10% versus prior corresponding period, indicating early traction under partner-based supply.
Underlying Earnings Improvement (Ex-FX)
Excluding foreign exchange movements, underlying EBIT and NPAT improved by approximately $0.5m in the period, indicating operational progress after adjusting for FX noise.
Medical Developments International Limited (AU:MVP) Earnings, Revenues Date & History
AU:MVP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:MVP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 18, 2026 | AU$0.46 | AU$0.46 | 0.00% |
Aug 20, 2025 | AU$0.64 | AU$0.62 | -3.13% |
Feb 19, 2025 | AU$0.76 | AU$0.84 | +10.53% |
Feb 28, 2024 | AU$0.85 | AU$0.87 | +2.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Medical Developments International Limited (AU:MVP) report earnings?
Medical Developments International Limited (AU:MVP) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).
What is Medical Developments International Limited (AU:MVP) earnings time?
Medical Developments International Limited (AU:MVP) earnings time is at Aug 20, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Medical Developments International Limited stock?
The P/E ratio of Medical Developments International Limited is N/A.
What is AU:MVP EPS forecast?
AU:MVP EPS forecast for the fiscal quarter 2026 (Q4) is >-0.01.